75%Confidence
0Views
FDASource
2026-04-10Date
Summary
Amerisource Health Services recalls Meclizine tablets due to failed specifications, reflecting quality lapses in distributed generic products that could affect their distribution agreements. This may prompt retailers to seek more reliable suppliers, impacting Amerisource's revenue from over-the-counter motion sickness drugs.
Actionable: Review Amerisource's distribution portfolio for other quality risks and consider diversifying suppliers for affected products.
AI Confidence: 75%
Data Points
firmAmerisource Health Services LLC
classificationClass II
statusOngoing
distributionU.S. Nationwide
productMeclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Dis
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now